Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes …
U.S. President Donald Trump stands, after delivering remarks on tariffs, in the Rose Garden at the White House in Washington, D.C., U.S., April 2, 2025. Leah Millis | Reuters Global markets, businesses and long-standing geopolitical relationships were thrown into disarray on Thursday, the day after U.S. President Donald Trump announced …
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug …
Steve Christo | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk‘s blockbuster diabetes drug Ozempic may also help people drink less alcohol. That’s …
Workers walk past manufacturing equipment at Eli Lilly & Co. manufacturing plant in Kinsale, Ireland, on Sept. 12, 2024. Lilly has been bulking up its production capacity since 2020, investing more than $17 billion into developing new plants and expanding existing facilities for the weight-loss and diabetes drugs that are …
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as …
“My pathway led by confusion boats / mutiny from stern to bow.” That phrase, from Bob Dylan’s 1964 classic, “My Back Pages,” seeped into my head Friday afternoon, as I sought to reevaluate the role of tech in the Charitable Trust. We had just reviewed Eaton’s very good — though …
Robert Kennedy Jr., U.S. President-elect Donald Trump’s nominee to run the Department of Health and Human Services, arrives at the Hart Senate Office Building on Capitol Hill in Washington, U.S., December 16, 2024. Benoit Tessier | Reuters As Robert F. Kennedy Jr. faces two days of Senate confirmation hearings this …
Wall Street rediscovered its winning ways last week, thanks to some promising inflation data. Investors are now focusing on Donald Trump’s first week back in the White House and another bundle of earnings. It was no surprise to see relatively muted action last Monday and Tuesday, given markets were reeling …